Literature DB >> 22586154

Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation.

Eve E Weatherill1, Katharine L Cain, Sam P Heywood, Joanne E Compson, James T Heads, Ralph Adams, David P Humphreys.   

Abstract

Engineered introduction of interface interchain disulphide bonds is perceived to be a simple method to increase the stability of single chain Fv (scFv). Six disulphide bond locations have been cited within the literature but the potential for the broad use of each has not been examined. Five of these disulphide bond locations were introduced into one scFv in order to compare their relative effects on expression, thermal stability, percent monomer formation and retention of antigen binding. The disulphide bond position vH44-vL100 was observed to enable the most favourable balance of biophysical properties. The vH44-vL100 disulphide bond was introduced into five additional scFv in both vL-vH and vH-vL orientations in order to investigate its general applicability. Data are presented to show the relative influence of scFv sequence, v-region organisation and interchain disulphide bond on expression yield, thermal stability and percent monomer. Introduction of the vH44-vL100 disulphide bond typically resulted in no or little increase in thermal stability and no change in percent monomer but did confer the benefit of permanently fixing monomer:dimer ratios during purification and analysis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22586154     DOI: 10.1093/protein/gzs021

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  18 in total

Review 1.  The impact of structural biology in medicine illustrated with four case studies.

Authors:  Tiancen Hu; Elizabeth R Sprague; Michelle Fodor; Travis Stams; Kirk L Clark; Sandra W Cowan-Jacob
Journal:  J Mol Med (Berl)       Date:  2017-07-01       Impact factor: 4.599

2.  Heat-induced irreversible denaturation of the camelid single domain VHH antibody is governed by chemical modifications.

Authors:  Yoko Akazawa-Ogawa; Mizuki Takashima; Young-Ho Lee; Takahisa Ikegami; Yuji Goto; Koichi Uegaki; Yoshihisa Hagihara
Journal:  J Biol Chem       Date:  2014-04-16       Impact factor: 5.157

3.  Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.

Authors:  Robert J Benschop; Chi-Kin Chow; Yu Tian; James Nelson; Barbra Barmettler; Shane Atwell; David Clawson; Qing Chai; Bryan Jones; Jon Fitchett; Stacy Torgerson; Yan Ji; Holly Bina; Ningjie Hu; Mahmoud Ghanem; Joseph Manetta; Victor J Wroblewski; Jirong Lu; Barrett W Allan
Journal:  MAbs       Date:  2019-06-10       Impact factor: 5.857

4.  Novel strategy for a bispecific antibody: induction of dual target internalization and degradation.

Authors:  J M Lee; S H Lee; J-W Hwang; S J Oh; B Kim; S Jung; S-H Shim; P W Lin; S B Lee; M-Y Cho; Y J Koh; S Y Kim; S Ahn; J Lee; K-M Kim; K H Cheong; J Choi; K-A Kim
Journal:  Oncogene       Date:  2016-02-08       Impact factor: 9.867

Review 5.  Tumor buster - where will the CAR-T cell therapy 'missile' go?

Authors:  Chunrun Qu; Hao Zhang; Hui Cao; Lanhua Tang; Haoyang Mo; Fangkun Liu; Liyang Zhang; Zhenjie Yi; Lifu Long; Luzhe Yan; Zeyu Wang; Nan Zhang; Peng Luo; Jian Zhang; Zaoqu Liu; Weijie Ye; Zhixiong Liu; Quan Cheng
Journal:  Mol Cancer       Date:  2022-10-19       Impact factor: 41.444

6.  Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.

Authors:  Ming Cheng; Mahiuddin Ahmed; Hong Xu; Nai-Kong V Cheung
Journal:  Int J Cancer       Date:  2014-06-19       Impact factor: 7.396

7.  Exploration and Modulation of Antibody Fragment Biophysical Properties by Replacing the Framework Region Sequences.

Authors:  Thomas Cnudde; Zineb Lakhrif; Justine Bourgoin; Fanny Boursin; Catherine Horiot; Corinne Henriquet; Anne di Tommaso; Matthieu Olivier Juste; Isabella Gizzi Jiacomini; Isabelle Dimier-Poisson; Martine Pugnière; Marie-Nöelle Mévélec; Nicolas Aubrey
Journal:  Antibodies (Basel)       Date:  2020-04-15

8.  Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting.

Authors:  Hannah A D King; Christopher A Gonelli; Kirsteen M Tullett; Mireille H Lahoud; Damian F J Purcell; Heidi E Drummer; Pantelis Poumbourios; Rob J Center
Journal:  PLoS One       Date:  2019-08-20       Impact factor: 3.240

9.  Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.

Authors:  Alkistis N Mitropoulou; Tom Ceska; James T Heads; Andrew J Beavil; Alistair J Henry; James M McDonnell; Brian J Sutton; Anna M Davies
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2020-03-02       Impact factor: 1.056

10.  Single chain variable fragment against aβ expressed in baculovirus inhibits abeta fibril elongation and promotes its disaggregation.

Authors:  Ying Zhang; Hai-Qiang Yang; Fang Fang; Lin-Lin Song; Yue-Ying Jiao; He Wang; Xiang-Lei Peng; Yan-Peng Zheng; Jun Wang; Jin-Sheng He; Tao Hung
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.